Efficacy and Safety of Tocilizumab in Monotherapy, an Anti-II-6 Receptor Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis: Results from a 24 Week Double-Blind Phase III Study

Maria Vinall

doi:10.1177/155989770600600307

Maria Vinall

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
View author's works on this site

Norihiro Nishimoto

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
View author's works on this site

Article
Info & Metrics
eLetters
PDF

Article Information

DOI

http://dx.doi.org/10.1177/155989770600600307

Published By

SAGE Publications

Print ISSN

1559-8977

Online ISSN

2155-756X

Author Information

Maria Vinall

Norihiro Nishimoto, MD

View Full Text

Article usage

	Abstract	Full	PDF
Apr 2015	7	0	0
May 2015	4	0	0
Jul 2015	0	1	1
Aug 2015	5	0	0
Oct 2015	1	4	2
Nov 2015	2	3	2
Total	19	8	5

Note: Article usage statistics are calculated and reported monthly.

Cited By...

No citing articles found.

Google Scholar

PreviousNext

Tools

Download PDF

View Full Page PDF

Citation Tools

Efficacy and Safety of Tocilizumab in Monotherapy, an Anti-II-6 Receptor Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis: Results from a 24 Week Double-Blind Phase III Study

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Thank you for your interest in spreading the word on MD Conference Express.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Efficacy and Safety of Tocilizumab in Monotherapy, an Anti-II-6 Receptor Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis: Results from a 24 Week Double-Blind Phase III Study

Message Subject (Your Name) has sent you a message from MD Conference Express

Message Body (Your Name) thought you would like to see the MD Conference Express web site.

Your Personal Message

Efficacy and Safety of Tocilizumab in Monotherapy, an Anti-II-6 Receptor Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis: Results from a 24 Week Double-Blind Phase III Study

Permalink: Copy

Linkedin Share Button